RT Journal Article
SR Electronic
T1 Atelectasis and survival after bronchoscopic lung volume reduction for COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP erj01001-2010
DO 10.1183/09031936.00100110
A1 N.S. Hopkinson
A1 S.V. Kemp
A1 T.P. Toma
A1 D.M. Hansell
A1 D.M. Geddes
A1 P.L. Shah
A1 M.I. Polkey
YR 2010
UL http://erj.ersjournals.com/content/early/2010/10/14/09031936.00100110.abstract
AB Bronchoscopic therapies to reduce lung volumes in COPD are intended to avoid the risks associated with lung volume reduction surgery, or to be used in patient groups in whom LVRS is not appropriate.Bronchoscopic lung volume reduction, using endobronchial valves, to target unilateral lobar occlusion can improve lung function and exercise capacity in patients with emphysema. Benefit is most pronounced in, though not confined to, patients where lobar atelectasis occurred. Few data exist on their long term outcome.19 patients (16 male) FEV1 28.4(11.9) underwent BLVR between July 2002 and February 2004. Radiological atelectasis was observed in 5 patients. Survival data to February 2010 was available for all patients.None of the patients in whom atelectasis occurred died during follow up whereas 8 out of 14 in the non-atelectasis group died (Chi2 p=0.026). There was no significant difference between the groups at baseline in lung function, quality of life, exacerbation rate, exercise capacity (shuttle walk test or cycle ergometry) or CT appearances, although BMI was significantly higher in the atelectasis group 21.6(2.9) vs 28.4(2.9)kg.m−2 (p<0.001).These data suggest that atelectasis following BLVR is associated with a survival benefit which is not explained by baseline differences.